Drugs / CBD
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06544291 Comparator | Oct 2024 → Jan 2028 expected | chronic pain syndrome, opiate dependence | Yale University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06544291 ↗ |
| Route | Oral | “orally administered combined delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)” NCT06544291 ↗ |